Check the Kras gene has become the treatment of colorectal cancer approach

Due to advances in molecular biology, found that some liver gene mutation or DNA changes happen many types of drugs can cause different reactions and side effects of the increase or reduction, such as lung epithelial growth factor receptor (EGFR) mutations were generated to target drugs such as Iressa or Tarceva have relatively good efficacy, but the wild-type (EGFR wild type) although there is no effect of mutant, but still has a certain effect, so for the wild-type group also they should not refuse treatment. But since 2006 found that the availability of colorectal cancer in patients with mutations in Kras target for drug treatment is effective, has a very clinical phase of clearance. 

In the EGFR inhibitor cetuximab or Medium panitimumab, KRAS mutation and treatment efficacy have not greatly affected. In other words, when EGFR mutations have used the two target drugs are not curative, that is, whether the combined chemotherapy of their clinical efficacy of cetuximab did not make much difference. Therefore, in the United States and Taiwan also began to study the use of EGFR inhibitors, colorectal cancer is best to first check whether Kras gene mutation, if mutation has suggested that non-use of cetuximab. Kras mutation that accounts for nearly 30 ~ 40% as much as, if prior inspection Kras gene mutations in patients who have no need to use the target treatment can not only reduce the occurrence of side effects can also reduce unnecessary costs, because the cost of expensive drug target , for the people, society and country are a great burden.